在这里,我们描述了针对口服活性EP1拮抗剂的一系列新的苯并[d]噻唑衍生物的设计,合成和评估。铅生成研究从四个设计的支架中提供了苯并[d]噻唑核心。根据EP1拮抗剂效能和配体亲脂性效率(LLE; pIC50-clogP)对该支架进行优化,可得到1,2,3,6-四氢吡啶基取代的苯并[d]噻唑衍生物7r(IC50 1.1nM; LLE 4.7),当在17-苯基trinor-PGE2(17-PTP)诱导的大鼠膀胱过度活动症模型中十二指肠内给药时显示出良好的药理作用。
PBr3-mediated reductivedeoxygenation of α-aryl-pyridinemethanols to provide arylmethylpyridines is described, the alcohol substrate scope is explored, free radical trap TEMPO (2,2,6,6-tetramethyl-1-piperidinyloxy) is introduced, and the hydrogen source of the methylene product is defined. The unexpected reaction enabled us to prepare previously inaccessible, novel EP1 antagonists.